Macclesfield, United Kingdom
Blueberry Therapeutics Ltd, founded in 2011 and based in the United Kingdom, is a biotechnology company specializing in topical nanomedicines for treating dermatological conditions. The company focuses on developing safe and effective treatments for skin diseases by leveraging state-of-the-art preclinical research technologies to create potent, selective molecules designed to minimize toxicity and enhance efficacy.
Key programs target conditions like Onychomycosis, Tinea Pedis, Acne, and Atopic Dermatitis. By employing innovative clinical designs, Blueberry aims to expedite trial processes and reduce associated costs, ensuring rapid progression from clinical proofs-of-concept to market-ready therapies with full regulatory and ethical compliance.
The company's last funding round was a £750.00K late venture capital investment on 01 June 2021, led by the Northern Powerhouse Investment Fund. This investment supports Blueberry's mission of developing new and safer dermatological treatments.
